Organization
Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Boston
1 abstract
Abstract
ACR-HYBRID ANALYSIS CONFIRMS BENEFIT OF CERTOLIZUMAB PEGOL WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE RAPID 1 AND 2 TRIALSOrg: Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, School of Medicine, Boston University, Boston, United States, Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Boston, Division of Immunology/Rheumatology, Stanford University, Stanford, Research and Development, UCB, Inc, Smyrna, United States,